COMPARISON OF INTRANASAL CORTICOSTEROIDS WITH ALLERGEN AVOIDANCE FOR THE MANAGEMENT OF PERSISTENT RHINITIS

Completed

• Conditions: Persistent Allergic Rhinitis; Inflammatory and Immune System - Allergies

• Registration Number: ACTRN12605000513617
• Lead Sponsor: niversity of Sydney (Pharmacology Department)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Physician-diagnosed, persistent allergic rhinitis. Mite allergic (SPT wheal >2mm than +ve histamine control). Have >75% of their total domestic mite allergen exposure while in bed. Have daily symptoms of rhinitis that will enable an improvement to be measured. No asthma, or have only mild to moderate asthma (as classified by Physician). Willing, able and otherwise suitable to participate and perform the required interventions.

Exclusion Criteria

Existing daily use of oral or topical intra-nasal corticosteroids. Severe asthma (as classified by Physician). Have an existing combination of allergies to other (non-mite) domestic allergens and associated exposure to these allergens that may compromise the effectiveness of the planned intervention directed at mite allergen exposure. For example, being cat allergic and being exposed to a cat at home would serve to exclude, as the intervention in beds cannot control cat allergen exposure in the house. However if there is cat allergy but no cat exposure, or cat exposure but no cat allergy, then this is not grounds for exclusion. Pregnancy. Current or recent history of a purulent nasal infection. Nasal Polyps. Exclusion criteria for the medication include tuberculosis, herpes simplex of the eye, recent nasal surgery or untreated nasal infections. Complete nasal obstruction.

Study & Design

• Study Type: Interventional
• Study Design: Not specified